Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
מצבים רפואיים
Glioblastoma Multiforme
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
University of Southern California, Los Angeles, California, United States
Contact: Principal Investigator (Frances Chow, MD)Saint John Cancer Institute, Santa Monica, California, United States
Contact: Principal Investigator (Naveed Wagle, MD)Georgia Cancer Center (Augusta University), Augusta, Georgia, United States
Contact: Principal Investigator (Gerald Wallace)Ochsner Health, New Orleans, Louisiana, United States
Contact: Principal Investigator (Caroline Goldin)Atlantic Health (Overlook Medical Center), Summit, New Jersey, United States
Contact: Principal Investigator (Robert Aiken)Northwell Health, New York, New York, United States
Contact: Principal Investigator (Samuel Singer)Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Cleveland Clinic, Cleveland, Ohio, United States
Contact: Principal Investigator (David Peereboom, MD)Baylor Scott & White Health, Dallas, Texas, United States
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Contact: Study coordinator (Noah Puente)University of Washington Medical Center, Seattle, Washington, United States
Contact: Study coordinator (Maciej Mrugala)University of Wisconsin Hospital and Clinic, Madison, Wisconsin, United States
Contact: Study coordinator (Steve Howard, MD)
מובילי המחקר
Thomas Chen, MD, PhD
Study Chair
NeOnc Technologies Holdings, Inc.
Josh Neman, PhD
Study Director
NeOnc Technologies Holdings, Inc.